TY - JOUR
T1 - Anti-Ebola therapies based on monoclonal antibodies
T2 - current state and challenges ahead
AU - González-González, Everardo
AU - Alvarez, Mario Moisés
AU - Márquez-Ipiña, Alan Roberto
AU - Trujillo-de Santiago, Grissel
AU - Rodríguez-Martínez, Luis Mario
AU - Annabi, Nasim
AU - Khademhosseini, Ali
N1 - Publisher Copyright:
© 2015 Taylor & Francis.
PY - 2017/1/2
Y1 - 2017/1/2
N2 - The 2014 Ebola outbreak, the largest recorded, took us largely unprepared, with no available vaccine or specific treatment. In this context, the World Health Organization declared that the humanitarian use of experimental therapies against Ebola Virus (EBOV) is ethical. In particular, an experimental treatment consisting of a cocktail of three monoclonal antibodies (mAbs) produced in tobacco plants and specifically directed to the EBOV glycoprotein (GP) was tested in humans, apparently with good results. Several mAbs with high affinity to the GP have been described. This review discusses our current knowledge on this topic. Particular emphasis is devoted to those mAbs that have been assayed in animal models or humans as possible therapies against Ebola. Engineering aspects and challenges for the production of anti-Ebola mAbs are also briefly discussed; current platforms for the design and production of full-length mAbs are cumbersome and costly.
AB - The 2014 Ebola outbreak, the largest recorded, took us largely unprepared, with no available vaccine or specific treatment. In this context, the World Health Organization declared that the humanitarian use of experimental therapies against Ebola Virus (EBOV) is ethical. In particular, an experimental treatment consisting of a cocktail of three monoclonal antibodies (mAbs) produced in tobacco plants and specifically directed to the EBOV glycoprotein (GP) was tested in humans, apparently with good results. Several mAbs with high affinity to the GP have been described. This review discusses our current knowledge on this topic. Particular emphasis is devoted to those mAbs that have been assayed in animal models or humans as possible therapies against Ebola. Engineering aspects and challenges for the production of anti-Ebola mAbs are also briefly discussed; current platforms for the design and production of full-length mAbs are cumbersome and costly.
UR - http://www.scopus.com/inward/record.url?scp=84948160387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948160387&partnerID=8YFLogxK
U2 - 10.3109/07388551.2015.1114465
DO - 10.3109/07388551.2015.1114465
M3 - Review article
C2 - 26611830
AN - SCOPUS:84948160387
SN - 0738-8551
VL - 37
SP - 53
EP - 68
JO - Critical Reviews in Biotechnology
JF - Critical Reviews in Biotechnology
IS - 1
ER -
